Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
20 hedge funds and large institutions have $6.96M invested in Interpace Biosciences, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
85% more capital invested
Capital invested by funds: $3.76M → $6.96M (+$3.2M)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$1.55M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.35M |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$838K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$251K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$376K |
| 2 |
VF
Virtu Financial
New York
|
-$73.9K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$24K |
| 4 |
MWM
Merriman Wealth Management
Seattle,
Washington
|
-$9K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$6K |
IDXG Hedge Fund Activity: Q1 2019 in Review
20 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2019, worth a combined $6.96M — up 85% from $3.76M a quarter earlier.
Fund positioning in IDXG was balanced in Q1 2019: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 3 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $1.55M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $376K.
- 20 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $6.96M of Interpace Biosciences, Inc. Common Stock stock for Q1 2019, up 85% quarter-over-quarter.
- 4 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2019 and 4 closed out, a net change of 0 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2019 was Sio Capital Management, an estimated $1.55M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2019 was Schonfeld Strategic Advisors, an estimated $376K sold.
Based on aggregated 13F filings for Q1 2019.